Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome

Journal of Clinical Lipidology

Volumn 2, Issue 4, 2008, Pages 279-284

  Filippatos, Theodosios D ^a   Tsimihodimos, Vasilis ^a   Kostapanos, Michael ^a   Kostara, Christina ^a   Bairaktari, Eleni T ^a   Kiortsis, Dimitrios N ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Apolipoprotein C II; Apolipoprotein C III; Fenofibrate; Orlistat; Triglycerides

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; FENOFIBRATE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; TURBIDIMETRY;

EID: 48549104782     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2008.06.001     Document Type: Article

References (49)

1. Kiortsis D.N., Filippatos T.D., and Elisaf M.S. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 31 (2005) 15-22
2. Muls E., Kolanowski J., Scheen A., and Van Gaal L. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 25 (2001) 1713-1721
3. Davidson M.H., Hauptman J., DiGirolamo M., et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281 (1999) 235-242
4. Hollander P.A., Elbein S.C., Hirsch I.B., et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 21 (1998) 1288-1294
5. Sjostrom L., Rissanen A., Andersen T., et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 352 (1998) 167-172
6. Torgerson J.S., Hauptman J., Boldrin M.N., and Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27 (2004) 155-161
7. Derosa G., Mugellini A., Ciccarelli L., and Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 25 (2003) 1107-1122
8. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 18 (2002) 269-276
9. Tsimihodimos V., Miltiadous G., Daskalopoulou S.S., Mikhailidis D.P., and Elisaf M.S. Fenofibrate: metabolic and pleiotropic effects. Curr Vasc Pharmacol 3 (2005) 87-98
10. Andersson Y., Majd Z., Lefebvre A.M., et al. Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation. Arterioscler Thromb Vasc Biol 19 (1999) 115-121
11. Haubenwallner S., Essenburg A.D., Barnett B.C., et al. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J Lipid Res 36 (1995) 2541-2551
12. Fruchart J.C., and Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc) 42 (2006) 39-64
13. Jong M.C., Hofker M.H., and Havekes L.M. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 19 (1999) 472-484
14. Wang C.S. Structure and functional properties of apolipoprotein C-II. Prog Lipid Res 30 (1991) 253-258
15. McConathy W.J., Gesquiere J.C., Bass H., Tartar A., Fruchart J.C., and Wang C.S. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 33 (1992) 995-1003
16. Filippatos T.D., Kiortsis D.N., Liberopoulos E.N., Georgoula M., Mikhailidis D.P., and Elisaf M.S. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res. Opin 21 (2005) 1997-2006
17. Filippatos T.D., Gazi I.F., Liberopoulos E.N., et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 193 (2007) 428-437
18. Filippatos T.D., Liberopoulos E.N., Kostapanos M., et al. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab 10 (2008) 476-483
19. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report (2002). Circulation. 2002;106:3143-3421.
20. Sakurabayashi I., Saito Y., Kita T., Matsuzawa Y., and Goto Y. Reference intervals for serum apolipoproteins A-I, A-II, B, C-II, C-III, and E in healthy Japanese determined with a commercial immunoturbidimetric assay and effects of sex, age, smoking, drinking, and Lp(a) level. Clin Chim Acta 312 (2001) 87-95
21. Lucas C.P., Boldrin M.N., and Reaven G.M. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol 91 (2003) 961-964
22. Reaven G., Segal K., Hauptman J., Boldrin M., and Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 87 (2001) 827-831
23. Caslake M.J., and Packard C.J. Phenotypes, genotypes and response to statin therapy. Curr Opin Lipidol 15 (2004) 387-392
24. Kostapanos M.S., Milionis H.J., Filippatos T.D., et al. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther 29 (2007) 1403-1414
25. Bradley W.A., Hwang S.L., Karlin J.B., et al. Low-density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low-density lipoproteins. J Biol Chem 259 (1984) 14728-14735
26. Brown S.A., Via D.P., Gotto Jr. A.M., Bradley W.A., and Gianturco S.H. Apolipoprotein E-mediated binding of hypertriglyceridemic very low density lipoproteins to isolated low density lipoprotein receptors detected by ligand blotting. Biochem Biophys Res Commun 139 (1986) 333-340
27. Packard C.J., Demant T., Stewart J.P., et al. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res 41 (2000) 305-318
28. Reitsma J.B., Castro Cabezas M., de Bruin T.W., and Erkelens D.W. Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metabolism 43 (1994) 293-298
29. Olivecrona G., and Beisiegel U. Lipid binding of apolipoprotein CII is required for stimulation of lipoprotein lipase activity against apolipoprotein CII-deficient chylomicrons. Arterioscler Thromb Vasc Biol 17 (1997) 1545-1549
30. Verine A., Salers P., and Boyer J. Effects of apoproteins C on lipoprotein lipase activity bound to rat fat cells. Am J Physiol 243 (1982) E175-E181
31. Baggio G., Manzato E., Gabelli C., et al. Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients. J Clin Invest 77 (1986) 520-527
32. Fojo S.S., and Brewer H.B. Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II. J Intern Med 231 (1992) 669-677
33. Shachter N.S., Hayek T., Leff T., et al. Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. J Clin Invest 93 (1994) 1683-1690
34. Ishibashi S., Murase T., Takahashi K., Mori N., Kawakami M., and Takaku F. Plasma apolipoprotein CII levels in hypertriglyceridemia. Metabolism 35 (1986) 781-785
35. Schonfeld G., George P.K., Miller J., Reilly P., and Witztum J. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism 28 (1979) 1001-1010
36. Kowal R.C., Herz J., Weisgraber K.H., Mahley R.W., Brown M.S., and Goldstein J.L. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem 265 (1990) 10771-10779
37. Clavey V., Lestavel-Delattre S., Copin C., Bard J.M., and Fruchart J.C. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol 15 (1995) 963-971
38. Tsimihodimos V., Kakafika A., Tambaki A.P., et al. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res 44 (2003) 927-934
39. Insua A., Massari F., Rodriguez Moncalvo J.J., Ruben Zanchetta J., and Insua A.M. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study. Endocr Pract 8 (2002) 96-101
40. Chapman M.J. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 171 (2003) 1-13
41. Jong M.C., Rensen P.C., Dahlmans V.E., van der Boom H., van Berkel T.J., and Havekes L.M. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res 42 (2001) 1578-1585
42. Wang C.S., McConathy W.J., Kloer H.U., and Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 75 (1985) 384-390
43. Staels B., Vu-Dac N., Kosykh V.A., et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 95 (1995) 705-712
44. Fernandez M.L., Metghalchi S., Vega-Lopez S., Conde-Knape K., Lohman T.G., and Cordero-Macintyre Z.R. Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women. J Nutr Biochem 15 (2004) 717-721
45. Gervaise N., Garrigue M.A., Lasfargues G., and Lecomte P. Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes. Diabetologia 43 (2000) 703-708
46. Lee S.J., Campos H., Moye L.A., and Sacks F.M. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 23 (2003) 853-858
47. Gerber Y., Goldbourt U., Segev S., and Harats D. Indices related to apo CII and CIII serum concentrations and coronary heart disease: a case-control study. Prev Med 37 (2003) 18-22
48. Luc G., Fievet C., Arveiler D., et al. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM studyEtude Cas Temoins sur 'Infarctus du Myocarde. J Lipid Res 37 (1996) 508-517
49. Sacks F.M., Alaupovic P., Moye L.A., et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 102 (2000) 1886-1892